1h Free Analyst Time
Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 4, 6 and 2 respectively.
Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Musculoskeletal Disorders, Respiratory and Undisclosed which include indications Solid Tumor, Breast Cancer, Rheumatoid Arthritis, Melanoma, Metastatic Colorectal Cancer, Muscle Invasive Bladder Cancer (MIBC), Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Ankylosing Spondylitis (Bekhterev's Disease), Axial Spondyloarthritis, Bile Duct Cancer (Cholangiocarcinoma), Chronic Myelomonocytic Leukemia (CMML), Colon Carcinoma, Colorectal Cancer, Cutaneous Angiosarcoma, Cytokine Release Syndrome (Cytokine Storm), Fibrosarcoma, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hematological Tumor, Hepatocellular Carcinoma, Juvenile Myelomonocytic Leukemia (JMML), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Lung Disease, Lymphoma, Malignant Pleural Effusion, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neurotoxicity Syndromes, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Osteoarthritis, Ovarian Cancer, Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma and Unspecified.
Furthermore, this report also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
- The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
- Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development
- Abhelix LLC
- Aduro BioTech Inc
- Amgen Inc
- AstraZeneca Plc
- BioInvent International AB
- BriaCell Therapeutics Corp
- Cold Genesys Inc
- Cytonus Therapeutics Inc
- Epeius Biotechnologies Corp
- GlaxoSmithKline Plc
- Humabs BioMed SA
- Humanigen Inc
- I-Mab Biopharma Co Ltd
- Izana Bioscience Ltd
- Morphotek Inc
- Seagull Labs (I) Pvt Ltd
- Sillajen Biotherapeutics
- Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles
- Bria-IMT - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Bria-OTS - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products
- Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products
- Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones
- Featured News & Press Releases
- Dec 17, 2019: BriaCell to present at Biotech Showcase 2020 in San Francisco
- Dec 13, 2019: BriaCell announces clinical data as presented at the 2019 San Antonio Breast Cancer Symposium
- Dec 11, 2019: Humanigen's GM-CSF knockout data presented at the 2019 Annual Meeting of American Society of Hematology Receives Award
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indications, H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Products under Development by Companies, H1 2020 (Contd..3), H1 2020
- Products under Development by Companies, H1 2020 (Contd..4), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by Abhelix LLC, H1 2020
- Pipeline by Aduro BioTech Inc, H1 2020
- Pipeline by Amgen Inc, H1 2020
- Pipeline by AstraZeneca Plc, H1 2020
- Pipeline by BioInvent International AB, H1 2020
- Pipeline by BriaCell Therapeutics Corp, H1 2020
- Pipeline by Cold Genesys Inc, H1 2020
- Pipeline by Cytonus Therapeutics Inc, H1 2020
- Pipeline by Epeius Biotechnologies Corp, H1 2020
- Pipeline by GlaxoSmithKline Plc, H1 2020
- Pipeline by Humabs BioMed SA, H1 2020
- Pipeline by Humanigen Inc, H1 2020
- Pipeline by I-Mab Biopharma Co Ltd, H1 2020
- Pipeline by Izana Bioscience Ltd, H1 2020
- Pipeline by Morphotek Inc, H1 2020
- Pipeline by Seagull Labs (I) Pvt Ltd, H1 2020
- Pipeline by Sillajen Biotherapeutics, H1 2020
- Dormant Products, H1 2020
- Dormant Products, H1 2020 (Contd..1), H1 2020
- Dormant Products, H1 2020 (Contd..2), H1 2020
- Discontinued Products, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Mechanism of Actions, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abhelix LLC
- Aduro BioTech Inc
- Amgen Inc
- AstraZeneca Plc
- BioInvent International AB
- BriaCell Therapeutics Corp
- Cold Genesys Inc
- Cytonus Therapeutics Inc
- Epeius Biotechnologies Corp
- GlaxoSmithKline Plc
- Humabs BioMed SA
- Humanigen Inc
- I-Mab Biopharma Co Ltd
- Izana Bioscience Ltd
- Morphotek Inc
- Seagull Labs (I) Pvt Ltd
- Sillajen Biotherapeutics
